Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
Provided herein antibodies, activatable antibodies (AAs), bispecific antibodies, and bispecific activatable antibodies (BAAs). Also provided herein are methods of making and methods of use of these antibodies, AAs, bispecific antibodies, and BAAs.
1. An isolated polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 78-84 (MM).
2. The isolated polypeptide of claim 1 , wherein the isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 78.
3. The isolated polypeptide of claim 1 , further comprising a cleavable moiety (CM).
4. The isolated polypeptide of claim 3 , wherein the CM comprises a substrate cleavable by a serine protease or a matrix metalloproteinase (MMP).
5. The isolated polypeptide of claim 4 , wherein the protease is an MMP.
6. The isolated polypeptide of claim 4 , wherein the protease is a serine protease.
7. The isolated polypeptide of claim 6 , wherein the serine protease is matriptase or uPA.
8. The isolated polypeptide of claim 3 , comprising a linker between the MM and the CM.
9. The isolated polypeptide of claim 3 , wherein the MM and the CM are not separated by a linker.
10. The isolated polypeptide of claim 3 , wherein the isolated polypeptide comprises a linker at the carboxyl terminus of the CM.
11. The isolated polypeptide of claim 3 , wherein the isolated polypeptide comprises a formula selected from the group consisting of:
i) (MM)-L1-(CM);
ii) (MM)-(CM)-L2;
iii) (MM)-L1-(CM)-L2; and
iv) (MM)-(CM),
wherein L1 and L2 are linkers.
12. The isolated polypeptide of claim 11 , wherein L1 and L2 are the same.
13. The isolated polypeptide of claim 11 , wherein L1 and L2 are different.